bendamustine + gemcitabine + bortezomib

This is a combination chemotherapy regimen consisting of three agents: bendamustine, gemcitabine, and bortezomib. Each drug has a distinct mechanism of action targeting cancer cells: - Bendamustine is an alkylating agent (nitrogen mustard derivative) that causes DNA crosslinking and strand breaks, leading to apoptosis in malignant cells. It is primarily used for indolent B-cell non-Hodgkin lymphoma and has been studied in various combinations for relapsed or refractory lymphomas[1][4]. - Gemcitabine is a nucleoside analog (antimetabolite) that inhibits DNA synthesis by incorporating into DNA during replication, resulting in cell death. - Bortezomib is a proteasome inhibitor that blocks the 26S proteasome, disrupting protein degradation pathways essential for cancer cell survival and proliferation[2]. This triplet regimen may be considered investigational; while combinations such as bendamustine with gemcitabine or with bortezomib are documented in clinical practice guidelines and trials for hematologic malignancies (e.g., Hodgkin lymphoma, multiple myeloma), the specific triple combination's use appears limited to advanced or refractory cases where standard therapies have failed[5][6]. The regimen would be administered intravenously.

Other names

苯达莫司汀 + 吉西他滨 + 硼替佐米